Your browser doesn't support javascript.
loading
Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
Cheung, Patrick; Patel, Samir; North, Scott A; Sahgal, Arjun; Chu, William; Soliman, Hany; Ahmad, Belal; Winquist, Eric; Niazi, Tamim; Patenaude, Francois; Lim, Gerald; Heng, Daniel Yick Chin; Dubey, Arbind; Czaykowski, Piotr; Wong, Rebecca K S; Swaminath, Anand; Morgan, Scott C; Mangat, Rupi; Keshavarzi, Sareh; Bjarnason, Georg A.
Afiliação
  • Cheung P; Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Patel S; Division of Radiation Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
  • North SA; Division of Medical Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
  • Sahgal A; Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Chu W; Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Soliman H; Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Ahmad B; Division of Radiation Oncology, Department of Oncology, London Health Sciences Centre, Western University, London, ON, Canada.
  • Winquist E; Division of Medical Oncology, Department of Oncology, London Health Sciences Centre, Western University, London, ON, Canada.
  • Niazi T; Division of Radiation Oncology, Department of Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
  • Patenaude F; Department of Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
  • Lim G; Division of Radiation Oncology, Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
  • Heng DYC; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
  • Dubey A; Department of Radiation Oncology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.
  • Czaykowski P; Department of Medical Oncology and Hematology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.
  • Wong RKS; Radiation Medicine Program, Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Swaminath A; Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
  • Morgan SC; Division of Radiation Oncology, Department of Radiology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada.
  • Mangat R; Ozmosis Research Inc., Toronto, ON, Canada.
  • Keshavarzi S; Department of Biostatistics, Princess Margaret Cancer Centre, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Bjarnason GA; Division of Medical Oncology, Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. Electronic address: georg.bjarnason@sunnybrook.ca.
Eur Urol ; 80(6): 693-700, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34399998
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Radiocirurgia / Neoplasias Renais Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Radiocirurgia / Neoplasias Renais Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article